3B BlackBio Dx Ltd concluded its one-on-one virtual investor meeting with Param Capital on Saturday, August 29, 2026. The session ran from 1:00 pm to 2:00 pm India Time.

The interaction focused on the company’s financial performance for the first quarter of FY27. Management used the Q1-FY27 Investor Presentation, previously intimated to stock exchanges via Ref. No. P-66/2026-27/27 dated August 13, 2026, as the basis for discussion.

Meeting Outcome

The company confirmed that only information available in the public domain was discussed during the call. No unpublished price-sensitive information was shared with the investor. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nikhil Kuber Dubey, Whole Time Director, signed the disclosure filed with the Bombay Stock Exchange.

The Board of Directors of 3B BlackBio Dx Limited approved the unaudited standalone and consolidated financial results for the first quarter of FY27 (ended June 30, 2026) on August 13, 2026. The company reported a 13% year-on-year increase in standalone net profit after tax (PAT) to ₹141.1 crore, supported by a significant rise in other income. In contrast, consolidated net profit declined by 29% to ₹89.8 crore, while revenue from operations decreased by 6% to ₹334.9 crore.

The company’s agrochemical business remains seasonal, with performance subject to weather conditions and cropping patterns, according to management disclosures. The divergence between standalone and consolidated results highlights the impact of subsidiary performance and non-controlling interests on group-level profitability.

Financial Performance

Consolidated total income stood at ₹396.3 crore for the quarter, down from ₹455.8 crore in the corresponding quarter of FY26. This decline was primarily driven by lower other income, which fell to ₹61.4 crore from ₹101.5 crore in the prior year period. Revenue from operations decreased to ₹334.9 crore from ₹354.3 crore.

Standalone total income from operations was ₹282.5 crore, up from ₹246.7 crore in Q1FY25. Standalone net profit before tax rose to ₹183.5 crore from ₹156.8 crore in the previous year. Depreciation and amortization expenses dropped sharply to ₹134.4 crore from ₹389.1 crore in the previous quarter, contributing to improved profitability margins despite lower top-line growth in the consolidated book.

Note: Consolidated PAT for Q1FY26 includes non-controlling interests adjustments; standalone figures reflect parent entity performance.

Segment-wise Results

The diagnostic kits segment continues to dominate the company’s financial performance. It contributed ₹320.6 crore in revenue, accounting for approximately 96% of total consolidated income. The segment generated a profit before interest and tax of ₹133.2 crore.

In contrast, the agrochemicals segment reported minimal revenue of ₹14.3 crore against ₹22.7 crore in the same quarter last year, reflecting its seasonal nature. The segment recorded a near-breakeven result with a profit of just ₹0.03 lakh.

What the Numbers Show

A notable divergence exists between standalone and consolidated profitability. While standalone PAT increased by 13% year-on-year, consolidated PAT attributable to owners of the parent declined significantly when comparing basic EPS figures (₹10.48 vs ₹14.76). This discrepancy highlights the impact of subsidiary performance and non-controlling interests on group-level results. Additionally, the sharp reduction in depreciation expenses—from ₹389.1 crore in Q4FY26 to ₹134.4 crore in Q1FY27—suggests potential changes in asset base or accounting treatments that warrant monitoring in subsequent quarters.

Corporate Actions

The board appointed M/s Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor based in Bhopal, as the Cost Auditor for FY27. The appointment complies with Section 148 of the Companies Act, 2013. Shareholders will ratify the remuneration at the upcoming Annual General Meeting.

Baheti & Co., the statutory auditors, completed their limited review of the financial statements. The audit report confirmed no material misstatements in compliance with SEBI Listing Regulations and Ind AS standards.